Europe Biotech Heavyweights Genmab And Argenx Ink Antibody Alliance
Starting With An Immunology And A Cancer Target
Executive Summary
The two flagship firms of the European biotech scene are pooling their technologies to jointly discover, develop and commercialize drugs against cancer and autoimmune diseases.
You may also be interested in...
Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Horizon's Revised TED Indication Should Help Tepezza
With Tepezza now clearly labeled for all thyroid eye disease patients, rather than just acute cases, Amgen can be more optimistic about economics around of its Horizon acquisition, analysts suggest.
Argenx’s I.V. Vyvgart May See Continued Role In ITP, Despite SubQ Version Coming
The company presented Phase III data for the I.V. formulation at ASH showing a high response rate in pretreated patients, a difficult-to-treat population. It also has a subcutaneous version in Phase III.